Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07445789) titled 'SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Martini Hospital Groningen
Condition:
Atrial Fibrillation (AF)
Intervention:
Drug: Verapamil 240 mg slow-release tablet
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: June 2026
Target Sample Size: 436
To know more, visit...